Cleerly

Healthcare organizations improve outcomes when they can deliver confident, consistent decisions. AI earns a place by removing diagnostic ambiguity — turning fragmented cardiac data into clarity clinicians can act on. In this Cleerly‑sponsored episode of the AI in Business podcast, Jim Hartman, Chief Commercial Officer at Cleerly, joins Emerj Artificial Intelligence Research’s Marilie Fouche to examine how AI can help close that gap. The conversation highlights a central challenge for hospitals: Ambiguity between tests and the clinical decision delays accurate diagnosis and complicates care pathways. Jim outlines three areas health systems evaluate when considering AI for cardiac imaging: • Clinical impact  • Workflow efficiency    • Financial return Jim offers leaders a clear way to evaluate AI in the full episode: https://lnkd.in/dwzXfPbF

The first-ever Harvard Medical School-affiliated Boston Sports Cardiology Summit kicks off today! 🫀 We're honored to join top clinical leaders at this premier event and share how our AI-powered platform enhances CCTA by delivering quantitative insights into the root cause of CAD. Connect with our team to see how Cleerly is helping advance #cardiovascularcare. #YesCCT #AIinHealthcare #PlaqueAnalysis

Discover how using Cleerly to characterize plaque, calculate stenosis, and flag likely vessel-specific ischemia consolidates multiple analyses into one streamlined workflow. Hear from expert Dr. Sami Abuzaid as he reviews the latest clinical evidence and real-world applications of Cleerly's personalized care pathway. *Dr. Abuzaid is a paid consultant for Cleerly. A. Sami Abuzaid MD,MHL FACP,FASE,FSCCT,FSCMR,FASNC,FSCAI,FEACVI,FESC,FACC #YesCCT #Cardiology #AIinHealthcare #CleerlyPartner #NASCI2026

Cleerly is officially one of @TIME's "World's Top Healthtech Companies of 2026"! 🏆 Thank you to our dedicated team and trusted partners. This is a testament to how we’re fundamentally changing the way cardiovascular risk is understood and managed! 💪❤️ Check out the full list here: https://lnkd.in/gMr_6s_V #HealthTech #DigitalHealth #TIME #Cardiology

The most advanced cardiovascular imaging in the world still leaves physicians with a critical question: what does this mean for my patient and what can I do about it? Cleerly can help answer that question. Not by replacing clinical judgment, but by making sure the imaging findings in front of you are as clear, complete, and actionable as possible. That means visibility down to vessels ≥1.5mm, customized reports designed for your team, and the ability to monitor plaque progression. Seeing clearly isn’t the finish line. It’s where confident decisions start. 💪❤️ 👉 Learn more: https://lnkd.in/g57XE-5S #YesCCT #CTFirst #AIinHealthcare

Transforming cardiac care takes more than innovative technology; it takes relentless execution. 💪❤️ Symone embodies Cleerly's HEART values, ensuring our clinical partners have the exact support they need to focus on what matters most: improving patient outcomes. If you're interested in joining a team of trailblazers working to create a world without heart attacks, check out our current openings: https://lnkd.in/eVMkYEmB #LifeatCleerly #EmployeSpotlight #AIinHealthcare

Before: one scan, one moment in time. After: a clear view of how coronary artery disease is changing and what that might mean for treatment. That shift is what we’re covering tomorrow with Dr. Kevin Young. Live Q&A included. 👉 Register today: https://lnkd.in/eypXeU3P #YesCCT #PlaqueAnalysis #Cardiology

🚀 Improve workflow efficiency with Cleerly Customized Reports. From custom intro sections to intelligent conditional logic and automated signature fields, our customized reports help eliminate repetitive manual edits so you can spend less time formatting reports and more time focused on patients and life outside the hospital. See what's possible with customized reports. 👉 Request a demo: https://lnkd.in/ei_wBjkp #YesCCT #HealthTech #AIinHealthcare

🚀 The standard for cardiac research is evolving. Today, we're revisiting some of the "Top 10 Cardiac CT Papers" from #SCCT2026. Judged by an independent panel of leading scientists, four of the year's top 10 papers featured data generated by Cleerly, highlighting the growing reliance on quantitative, AI-driven research. Notably, one of the top 5 papers demonstrates how AI-QCT improves risk prediction beyond standard visual CTA assessment: 🔹 Prognostic Value of AI-Based Quantitative Coronary CTA vs. Human Reader-Based Visual Assessment 🔗 https://lnkd.in/esrdUuDK Explore the other Cleerly-powered studies recognized this year: 🔹 Coronary Plaque Volume in an Asymptomatic Population 🔗 https://lnkd.in/eN9Q4rZA 🔹NATURal history of coronary PlaquE on cardiac computed tomography in individuals without MACE or lipid-lowering therapy: NATURE-CTstudy 🔗 https://lnkd.in/eXsDyBpJ 🔹 Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication 🔗 https://lnkd.in/eSwkvNwZ How do you see AI-driven data shaping the next era of cardiology? Let us know below. 👇 #YesCCT #Cardiology #AIQCT #ClinicalResearch

With #CCTA earning a Class 1, Level A recommendation for evaluating patients with stable and acute chest pain (ACC/AHA), the era of guessing is over. Join our Chief Medical, Science, and AI Officer, Udo Hoffmann MD MPH, at #ISCT2026 to see how Cleerly's advanced plaque analysis elevates this first-line diagnostic to help proactively transform #cardiaccare. 👉 Learn more: https://lnkd.in/eND373Fp #YesCCT #AIinHealthcare #DigitalHealth